<DOC>
	<DOCNO>NCT00622089</DOCNO>
	<brief_summary>DiObex Inc. develop experimental drug ( DIO-902 ) make part ketoconazole molecule treatment elevate blood glucose associate type 2 diabetes mellitus . Ketoconazole ( NizoralÂ® ) drug available prescription treatment fungal infection however DIO-902 investigational drug . DIO-902 may lower blood glucose lowering level naturally occur hormone call cortisol . Elevated cortisol may contribute development type 2 diabetes .</brief_summary>
	<brief_title>Open Label Safety &amp; Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin &amp; Atorvastatin T2DM Patients</brief_title>
	<detailed_description>To maintain blind Protocol DIO-502 , subject re-randomized Study Visit 1 one three dose DIO-902 : 150 , 300 450 mg QHS . All subject receive DIO-902 placebo 50 % subject receive DIO-902 re-randomized one three DIO-902 dos . The remain 50 % subject receive DIO-902 assign original DIO-902 dose . The re- randomization perform group independent study conduct ensure treatment status subject Protocol DIO-502 remain blind . In addition , subject continue dose metformin take conduct Protocol DIO-502 . Subjects continue atorvastatin 10 mg first 4 week protocol . Thereafter , Study Visits 3 4 , dose atorvastatin may increase maximum 40 mg daily order achieve LDL-cholesterol/non-HDL cholesterol goal specify within protocol . In addition , Study Visit 4 ( Week 12 ) subject HbA1c level &gt; 7.5 % ( 0.075 Hb Fract . ) undergo one time titration oral hypoglycemic regimen per algorithm provide protocol .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Participated DIO502 Did participate DIO502</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>diabetes</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>cholesterol</keyword>
</DOC>